DermaGen AB develops novel endogenous or semi-endogenous AMPs with a focus on primary target diseases within the dermatological field that can be treated with topical applications.
Our immediate potential markets are, but not limited to, atopic dermatitis, certain infected wounds like burn wounds and infected diabetic foot ulcers, acne, vaginitis, impetigo, and treatment of multiresistant bacteria.
In a longer perspective, other diseases where specific local and/or systemic administration is required may be possible to explore. Such indications include sepsis and urogenital infections.